Other languages Alvotech Nyse

Equities

ALVO

LU2458332611

Market Closed - Nyse Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
13.37 ^USD	-1.69%		+41.63%	+42.54%

Apr. 30	Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	MT
Apr. 30	Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	Apr. 30
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	Apr. 30
Alvotech Announces U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira	Apr. 30
Cigna to offer Humira rivals with $0 copay at specialty pharmacy	Apr. 25
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study	Apr. 24
Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi	Apr. 24
Alvotech Signs U.S. Agreement to Expand Access for Newly Approved High-Concentration Interchangeable Biosimilar to Humira®	Apr. 19
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	Apr. 17
J&J beats first-quarter profit estimates on cancer drugs strength	Apr. 16
Alvotech Provides Earnings Guidance for the Year 2024 and 2025	Mar. 21
Alvotech Full-Year 2023 Loss Narrows, Revenue Rises	Mar. 20
Alvotech Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20
Alvotech Announces Executive Changes	Feb. 29
Sector Update: Health Care Stocks Mixed Premarket Monday	Feb. 26
Alvotech, Teva Say Simlandi Receives US FDA Approval as Interchangeable Humira Biosimilar	Feb. 26
Sector Update: Health Care	Feb. 26
Alcoa : Berkshire Hathaway, Teva... les valeurs à suivre aujourd'hui à Wall Street -	Feb. 26
Teva Pharmaceutical Industries : attendu en hausse après l'approbation du Simlandi par la FDA	Feb. 26
Alvotech Agrees to $166 Million Share Sale Offer	Feb. 26
Alvotech and Teva Pharmaceuticals Announces U.S. Approval of SIMLANDI (Adalimumab-Ryvk) Injection	Feb. 23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alvotech Nyse

Equities

ALVO

LU2458332611

Other languages

Filters